Durgical
EN
Open the app

Malignant pleural effusion

Fluid that builds up around the lung because cancer has spread to its lining. It causes breathlessness; draining it and stopping it returning brings relief.

Updated

What it is

An exudative pleural effusion with cancer cells in the fluid or on the pleura, from a pleural tumour (mesothelioma) or, far more often, from metastases. It signals advanced, usually incurable cancer, so care aims at relieving breathlessness.

Who gets it

Lung cancer causes about a third and breast cancer about a quarter; lymphoma, ovarian and gastric cancers follow, and in about 1 in 10 the primary is never found. Up to about 15% of people with cancer develop one during their illness, and it is one of the commonest causes of an exudate in adults over 60. Median survival after diagnosis is roughly 3 to 12 months, depending on the tumour.

Causes

  • Metastatic carcinoma: lung (adenocarcinoma most often), breast, ovary, stomach, kidney and others
  • Lymphoma and leukaemia
  • Primary pleural tumour: malignant pleural mesothelioma
  • Cancer of unknown primary
  • Paramalignant effusions (no cancer cells in the pleura): mediastinal node obstruction of lymph drainage, superior vena cava obstruction, post-obstructive pneumonia or atelectasis, radiotherapy or drug effects

Risk factors

  • Known cancer, especially lung, breast, ovarian cancer or lymphoma
  • Smoking history
  • Asbestos exposure (mesothelioma)
  • Older age
  • Weight loss and other features of advanced disease

Pathophysiology

Tumour seeds the parietal and visceral pleura (or blocks the mediastinal nodes) → vascular endothelial growth factor and inflammation raise capillary permeability → protein-rich exudate pours into the pleural space → tumour also blocks the parietal pleural stomata and mediastinal lymphatics that drain the space → inflow exceeds outflow, so fluid builds up and returns after drainage → breathlessness from a stiff chest wall, a flattened or inverted diaphragm and compressed lung, more than from low oxygen → when tumour or fibrin encases the visceral pleura, the lung cannot re-expand (non-expandable or trapped lung) and pleurodesis cannot work.

Classification

  • Malignant (cancer cells in fluid or pleura) versus paramalignant (cancer-related, without pleural cancer)
  • Free-flowing versus loculated (septated)
  • Expandable lung versus non-expandable (trapped) lung after drainage: decides between pleurodesis and an indwelling catheter
  • By primary tumour, which drives prognosis and the chance of response to systemic therapy

Symptoms and signs

  • Progressive breathlessness, first on exertion
  • Dry cough
  • Dull, aching chest pain (constant pain suggests chest-wall invasion, typical of mesothelioma)
  • Weight loss, poor appetite and fatigue
  • Signs: stony dullness to percussion, reduced breath sounds and reduced tactile fremitus over the fluid

Diagnosis

Clinical
Suspected with a new, usually one-sided effusion in someone with known cancer, or an unexplained exudate in an older smoker; the history covers cancer, smoking and asbestos. In about half of cases the effusion is the first sign of the cancer.
Tests
Diagnostic thoracentesis: an exudate by Light's criteria, often blood-stained and lymphocytic. Cytology finds cancer cells in about 60%, more with a second sample; cell blocks allow immunohistochemistry and molecular testing (EGFR, ALK, PD-L1) that guide targeted therapy. Low pleural pH and glucose mean a heavier tumour burden, poorer survival and a lower chance of successful pleurodesis. If cytology is negative, an image-guided or thoracoscopic pleural biopsy gives the diagnosis in more than 90%. The LENT score (pleural LDH, performance status, blood neutrophil-to-lymphocyte ratio, tumour type) estimates survival.
Imaging
Chest radiograph shows the effusion. Thoracic ultrasound guides every tap and shows septations, pleural nodules and diaphragm thickening. Contrast CT favours malignancy when the pleura is nodular, circumferential, more than 1 cm thick or involves the mediastinal pleura, and looks for the primary. PET-CT helps stage selected patients.

Differential diagnosis

Exudate in an adult: cancer or a look-alike?

ConditionCluesPleural fluidConfirm with
Malignant pleural effusionKnown cancer, older smoker, weight loss; fluid returns after tappingExudate, often blood-stained and lymphocytic; low pH and glucose with heavy tumourCytology, then pleural biopsy
Tuberculous pleurisyYounger adult, fever, night sweats; common in ColombiaLymphocytic exudate with high adenosine deaminasePleural biopsy (granulomas) and culture
Parapneumonic effusion or empyemaFever and pneumoniaNeutrophilic; in empyema pus, low pH and glucose, positive Gram stainGram stain and culture of the fluid
Pleural mesotheliomaAsbestos exposure decades earlier, chest-wall painExudate, often bloodyThoracoscopic pleural biopsy
Heart failureOrthopnoea, raised neck veins, bilateral effusionsTransudate by Light's criteriaNatriuretic peptide and echocardiography

Goal of treatment

Relieve breathlessness and keep it from returning with the fewest procedures and days in hospital, matched to the person's wishes, prognosis and whether the lung re-expands. An asymptomatic effusion can be watched.

Treatment

Follow-up
No drainage for a small effusion that causes no symptoms; review for breathlessness. Early involvement of palliative care in every case.
Procedure
Therapeutic thoracentesis under ultrasound guidance relieves symptoms and shows whether breathing improves and the lung re-expands; it is stopped if chest tightness or cough appears. Repeated taps alone suit only people with very short life expectancy or slow reaccumulation.
Procedure
Tunnelled indwelling pleural catheter, drained at home by the patient, family or nurse: first choice when the lung is non-expandable, and an equal option to pleurodesis when it expands; it shortens hospital stay and often leads to spontaneous pleurodesis.
Procedure
Chemical pleurodesis with graded large-particle talc, as slurry through a chest drain or by poudrage at thoracoscopy, when the lung re-expands; talc can also be given through an indwelling catheter to speed its removal.
Surgical
Video-assisted thoracoscopic surgery with talc poudrage, adhesiolysis or, rarely, pleurectomy-decortication in fit patients, mainly with mesothelioma.
Medical
Systemic treatment of the cancer (chemotherapy, targeted therapy such as EGFR or ALK inhibitors, immunotherapy or hormone therapy) can control the effusion in sensitive tumours such as lymphoma, small-cell lung, breast and germ-cell cancers. Symptom relief: opioids for refractory breathlessness, analgesia, and oxygen only for low oxygen saturation.

Complications

  • Re-expansion pulmonary oedema after fast or large-volume drainage
  • Pneumothorax and bleeding from the procedure
  • Pleural infection or catheter-tract infection
  • Tumour growth along the catheter or needle tract (mainly mesothelioma)
  • Loculation and non-expandable (trapped) lung
  • Rarely, acute lung injury after talc (less with graded large-particle talc)

Common traps

  • A negative cytology rules out a malignant effusion: cytology finds cancer cells in only about 60%; repeat it once, then take a pleural biopsy
  • Draining the fluid is the treatment: a tap relieves breathlessness only for a while; plan a definitive option (indwelling catheter or pleurodesis) early
  • Pleurodesis suits every malignant effusion: it needs a lung that re-expands so the pleural layers touch; a trapped lung needs an indwelling pleural catheter
  • Oxygen relieves the breathlessness: it is mostly mechanical, so drainage relieves it; oxygen is only for low saturation
  • A lymphocytic exudate in an adult means cancer: in Colombia tuberculous pleurisy is a common cause; measure adenosine deaminase and take a pleural biopsy

Prognosis

Poor overall, because it means advanced cancer: median survival is a few months, and only longer in tumours that respond to treatment. Survival is shortest with lung cancer and longest with mesothelioma, breast cancer and lymphoma; the LENT score helps decide how invasive the treatment should be.

Test yourself

Think of the answer, then tap the question to see it.

Which two cancers cause most malignant pleural effusions?

Lung cancer (about a third) and breast cancer (about a quarter), followed by lymphoma and ovarian and gastric cancers.

A large effusion does not shift the mediastinum away. What does that suggest?

A blocked main bronchus with lung collapse, or a mediastinum fixed by tumour, as in mesothelioma; bronchoscopy may be needed before drainage.

Why is pleurodesis likely to fail with a non-expandable (trapped) lung?

The two pleural layers cannot touch, so they cannot fuse; an indwelling pleural catheter is the preferred option.

What do low pleural pH and glucose mean in a malignant effusion?

A heavy tumour burden in the pleura, shorter survival and a lower chance that pleurodesis succeeds.

A 62-year-old with past breast cancer has a large right effusion; a tap relieved her and the lung re-expanded, but fluid returned in 10 days; cytology: adenocarcinoma. Definitive options?

Talc pleurodesis or a tunnelled indwelling pleural catheter, both fine with an expandable lung; her preference, prognosis and home support decide. A trapped lung would mean the catheter.

Add to my cards (5)

Why it happens

Connections

Educational information, not medical advice. For any symptom, see a health professional.

Sources: Malignant Pleural Effusion (StatPearls (NCBI Bookshelf), 2024); Pleurodesis (StatPearls (NCBI Bookshelf), 2025).

← All conditions

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.